Mesenchymal stromal cells modulate gut inflammation in experimental colitis

Area of Science:

• Immunology
• Gastroenterology
• Regenerative Medicine

Background:

• Inflammatory bowel diseases (IBDs) affect millions globally, with increasing incidence in developed nations.
• Current research focuses on therapies that modulate inflammation and promote tissue regeneration for IBD treatment.
• Adipose tissue-derived mesenchymal stromal cells (ADMSCs) show immunomodulatory potential in inflammatory and autoimmune conditions.

Purpose of the Study:

• To investigate the immunomodulatory effects of ADMSCs in a dextran sulfate sodium (DSS)-induced colitis model.
• To assess ADMSC treatment's impact on colitis severity, inflammation markers, immune cell populations, and regulatory molecules.

Main Methods:

• Administered ADMSCs to mice with DSS-induced colitis.
• Evaluated colitis severity, colon length, and pathological scores.
• Quantified pro-inflammatory cytokines (IFN-γ, TNF-α, IL-6, MCP-1) and immune cell frequencies (macrophages, dendritic cells) in the colon.
• Measured levels of immunoregulatory molecules (arginase-1, IL-10) in the intestine.

Main Results:

• ADMSC treatment ameliorated DSS-induced colitis severity, reducing pathological scores and preventing colon shortening.
• A significant reduction in pro-inflammatory cytokines (IFN-γ, TNF-α, IL-6, MCP-1) was observed in ADMSC-treated mice.
• ADMSC therapy led to decreased frequencies of macrophages and dendritic cells in the intestinal lamina propria.
• Upregulation of immunoregulatory molecules, including arginase-1 and IL-10, was detected in the intestines of ADMSC-treated mice.

Conclusions:

• ADMSCs effectively modulate gut inflammation by reducing immune cell activation and recruitment in experimental colitis.
• These findings support the development of ADMSC-based therapies for intestinal diseases like IBD.
• ADMSC treatment offers a promising strategy for managing inflammatory conditions in the gut.